

Isaac P Witz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2558043/publications.pdf>

Version: 2024-02-01

118
papers

4,385
citations

126907

33
h-index

118850

62
g-index

121
all docs

121
docs citations

121
times ranked

5060
citing authors

#	ARTICLE	IF	CITATIONS
1	A Possible Role for CXCR4 and Its Ligand, the CXC Chemokine Stromal Cell-Derived Factor-1, in the Development of Bone Marrow Metastases in Neuroblastoma. <i>Journal of Immunology</i> , 2001, 167, 4747-4757.	0.8	370
2	A history of exploring cancer in context. <i>Nature Reviews Cancer</i> , 2018, 18, 359-376.	28.4	361
3	CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells. <i>Cancer Research</i> , 2007, 67, 3396-3405.	0.9	179
4	The Tumor Microenvironment: The Making of a Paradigm. <i>Cancer Microenvironment</i> , 2009, 2, 9-17.	3.1	164
5	The tumor microenvironment in the post-PAGET era. <i>Cancer Letters</i> , 2006, 242, 1-10.	7.2	135
6	The selectin-selectin ligand axis in tumor progression. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 19-30.	5.9	118
7	Yin-Yang Activities and Vicious Cycles in the Tumor Microenvironment. <i>Cancer Research</i> , 2008, 68, 9-13.	0.9	115
8	Tumor-Microenvironment Interactions: Dangerous Liaisons. <i>Advances in Cancer Research</i> , 2008, 100, 203-229.	5.0	113
9	Astrocytes facilitate melanoma brain metastasis via secretion of IL-23. <i>Journal of Pathology</i> , 2015, 236, 116-127.	4.5	95
10	Cancer drug resistance induced by EMT: novel therapeutic strategies. <i>Archives of Toxicology</i> , 2021, 95, 2279-2297.	4.2	92
11	The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2464-2474.	0.7	90
12	The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. <i>Immunology Letters</i> , 2004, 92, 171-178.	2.5	85
13	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. <i>Journal of Investigative Dermatology</i> , 2015, 135, 532-541.	0.7	79
14	Tumor-Bound Immunoglobulins: in Situ Expressions Of Humoral Immunity. <i>Advances in Cancer Research</i> , 1977, , 95-148.	5.0	78
15	The relationship between in vitro fertilization and naturally occurring antibodies: evidence for increased production of antiphospholipid autoantibodies. <i>Fertility and Sterility</i> , 1991, 56, 718-724.	1.0	75
16	The metastatic microenvironment: Brain-residing melanoma metastasis and dormant micrometastasis. <i>International Journal of Cancer</i> , 2012, 131, 1071-1082.	5.1	74
17	The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma. <i>Oncogene</i> , 2002, 21, 3969-3977.	5.9	72
18	PROTECTIVE AND CELLULAR IMMUNE RESPONSES TO IDIOTYPIC DETERMINANTS ON CELLS FROM A SPONTANEOUS LYMPHOMA OF NZB/NZW F1 MICE. <i>Journal of Experimental Medicine</i> , 1974, 140, 1547-1558.	8.5	71

#	ARTICLE	IF	CITATIONS
19	Hexokinase 2 is a determinant of neuroblastoma metastasis. British Journal of Cancer, 2016, 114, 759-766.	6.4	68
20	Tumor-associated immunoglobulins. enhancement of syngeneic tumors by igg2-containing tumor eluates. International Journal of Cancer, 1972, 9, 242-247.	5.1	65
21	CCR4 is a determinant of melanoma brain metastasis. Oncotarget, 2017, 8, 31079-31091.	1.8	65
22	Progression of mouse mammary tumors: MCP-1-TNF α cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. International Journal of Cancer, 2003, 106, 879-886.	5.1	62
23	Tumor-Microenvironment Interactions. Cancer Research, 2004, 64, 6571-6578.	0.9	62
24	Chemokine-chemokine receptor axes in melanoma brain metastasis. Immunology Letters, 2010, 130, 107-114.	2.5	61
25	The role played by the microenvironment in site-specific metastasis. Cancer Letters, 2014, 352, 54-58.	7.2	54
26	Tumor-bound immunoglobulins. Evidence for their vivo coating of tumor cells by potentially cytotoxic anti-tumor antibodies. International Journal of Cancer, 1976, 17, 90-97.	5.1	51
27	Tumor-associated immunoglobulins. The elution of IgG2 from mouse tumors. International Journal of Cancer, 1970, 6, 361-372.	5.1	48
28	Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Letters, 2015, 361, 86-96.	7.2	45
29	The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. International Journal of Cancer, 2015, 136, 1296-1307.	5.1	44
30	The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Letters, 2009, 273, 127-139.	7.2	42
31	Human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells. International Journal of Cancer, 2002, 98, 803-810.	5.1	40
32	The involvement of selectins and their ligands in tumor-progression. Immunology Letters, 2006, 104, 89-93.	2.5	40
33	Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress. , 1998, 77, 306-313.		36
34	MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunology Letters, 1999, 68, 141-146.	2.5	35
35	Cellular characteristics of neuroblastoma cells: regulation by the ELR ⁻ -CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine, 2005, 29, 105-117.	3.2	34
36	The metastatic microenvironment: Melanoma-microglia cross-talk promotes the malignant phenotype of melanoma cells. International Journal of Cancer, 2019, 144, 802-817.	5.1	34

#	ARTICLE	IF	CITATIONS
37	AN association between high Ly-6A/E expression on tumor cells and a highly malignant phenotype. <i>International Journal of Cancer</i> , 1994, 59, 684-691.	5.1	33
38	Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. <i>Oncogene</i> , 2003, 22, 7649-7660.	5.9	33
39	Overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukaemia. <i>Cancer Letters</i> , 2003, 199, 185-192.	7.2	32
40	Tumor-Microenvironment Interactions. <i>Cancer Treatment and Research</i> , 2006, , 125-140.	0.5	32
41	E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. <i>International Journal of Cancer</i> , 2008, 123, 1741-1750.	5.1	32
42	The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 14-26.	0.9	31
43	Natural host defence during oncogenesis. NK activity and dimethylbenzanthracene carcinogenesis. <i>International Journal of Cancer</i> , 1983, 31, 67-73.	5.1	30
44	Differential expression of genes by tumor cells of a low or a high malignancy phenotype: The case of murine and human Ly-6 proteins. <i>Journal of Cellular Biochemistry</i> , 2000, 77, 61-66.	2.6	29
45	The GPI-linked Ly-6 Antigen E48 Regulates Expression Levels of the FX Enzyme and of E-selectin Ligands on Head and Neck Squamous Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 12833-12840.	3.4	29
46	The metastatic microenvironment: Brain-derived soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells. <i>International Journal of Cancer</i> , 2012, 131, 2509-2518.	5.1	28
47	<sc>Site-specific</sc> metastasis: A cooperation between cancer cells and the metastatic microenvironment. <i>International Journal of Cancer</i> , 2021, 148, 1308-1322.	5.1	28
48	Serologically detectable specific and cross-reactive antigens on the membrane of a polyoma virus-induced murine tumor. <i>International Journal of Cancer</i> , 1976, 18, 243-249.	5.1	27
49	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. <i>Molecular Oncology</i> , 2020, 14, 1760-1778.	4.6	27
50	Increased Antiphospholipid Antibody Activity in In Vitro Fertilization Patients Is Not Treatment-Dependent but Rather an Inherent Characteristic of the Infertile State. <i>American Journal of Reproductive Immunology</i> , 1995, 34, 370-374.	1.2	25
51	The murine Fc-gamma (Fc ^γ) receptor type II B1 is a tumorigenicity-enhancing factor in polyoma-virus-transformed 3T3 cells. , 1996, 65, 221-229.		25
52	The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. <i>Immunology Letters</i> , 2004, 92, 163-169.	2.5	25
53	Tumor bound immunoglobulins: The relationship between their vivo coating of tumor cells by potentially cytotoxic anti-tumor antibodies, and the expression of immune complex receptors. <i>International Journal of Cancer</i> , 1976, 18, 116-121.	5.1	23
54	ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis. <i>Oncotarget</i> , 2017, 8, 75778-75796.	1.8	23

#	ARTICLE	IF	CITATIONS
55	The participation of trimethylammonium in the mouse erythrocyte epitope recognized by monoclonal autoantibodies. <i>Immunology Letters</i> , 1981, 3, 315-319.	2.5	22
56	Generation and Characterization of Novel Local and Metastatic Human Neuroblastoma Variants. <i>Neoplasia</i> , 2008, 10, 817-115.	5.3	22
57	Degradation of immunoglobulins by lysosomal enzymes of tumors. Demonstration of the phenomenon using mouse tumors. <i>Immunochemistry</i> , 1973, 10, 565-570.	1.2	21
58	FcR may function as a progression factor of nonlymphoid tumors. <i>Immunologic Research</i> , 1992, 11, 283-295.	2.9	21
59	Contribution of the intracellular domain of murine FC-gamma receptor type IIB1 to its tumor-enhancing potential. , 1996, 68, 219-227.		21
60	cDNA Microarray Analysis Reveals an Overexpression of the Dual-Specificity MAPK Phosphatase PYST2 in Acute Leukemia. <i>Methods in Enzymology</i> , 2003, 366, 103-113.	1.0	21
61	The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. <i>Immunology Letters</i> , 2008, 116, 218-224.	2.5	20
62	Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. <i>Cancer Treatment and Research</i> , 2006, 130, 125-40.	0.5	20
63	Characterization of immunoglobulins eluted from murine tumor cells: Binding patterns of cytotoxic anti-tumor IgG. <i>Journal of Immunological Methods</i> , 1978, 22, 51-62.	1.4	18
64	The metastatic microenvironment: Lung-derived factors control the viability of neuroblastoma lung metastasis. <i>International Journal of Cancer</i> , 2013, 133, 2296-2306.	5.1	18
65	Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. <i>Epigenomics</i> , 2015, 7, 1303-1311.	2.1	18
66	Gene expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. <i>International Journal of Cancer</i> , 2010, 126, 1570-1581.	5.1	17
67	Lung-Residing Metastatic and Dormant Neuroblastoma Cells. <i>American Journal of Pathology</i> , 2011, 179, 524-536.	3.8	17
68	The FX Enzyme Is a Functional Component of Lymphocyte Activation. <i>Cellular Immunology</i> , 2001, 213, 141-148.	3.0	16
69	Cystatin C takes part in melanoma-microglia cross-talk: A possible implications for brain metastasis. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 369-378.	3.3	16
70	Serological detection of a polyoma-tumor-associated membrane antigen. <i>International Journal of Cancer</i> , 1979, 23, 683-690.	5.1	15
71	Characterization of the dual-specificity phosphatase PYST2 and its transcripts. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 37-47.	2.8	15
72	P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway. <i>Cancer Letters</i> , 2017, 407, 66-75.	7.2	14

#	ARTICLE	IF	CITATIONS
73	Regeneration Enhances Metastasis: A Novel Role for Neurovascular Signaling in Promoting Melanoma Brain Metastasis. <i>Frontiers in Neuroscience</i> , 2019, 13, 297.	2.8	14
74	Receptors involved in microenvironment-driven molecular evolution of cancer cells. <i>Seminars in Cancer Biology</i> , 2002, 12, 139-147.	9.6	13
75	The elution of antibodies from viable murine tumor cells. <i>Journal of Immunological Methods</i> , 1979, 26, 345-353.	1.4	12
76	Phenotypic Properties of 3T3 Cells Transformed in vitro with Polyoma Virus and Passaged Once in Syngeneic Animals. <i>Immunobiology</i> , 1992, 185, 281-291.	1.9	12
77	The Challenge of Classifying Metastatic Cell Properties by Molecular Profiling Exemplified with Cutaneous Melanoma Cells and Their Cerebral Metastasis from Patient Derived Mouse Xenografts. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 478-489.	3.8	12
78	The melanoma brain metastatic microenvironment: aldolase C partakes in shaping the malignant phenotype of melanoma cells – a case of inter-tumor heterogeneity. <i>Molecular Oncology</i> , 2021, 15, 1376-1390.	4.6	12
79	Lymphocytotoxic Autoantibodies Eluted From In Vivo Propagating Sarcoma Cells of Mice: Brief Communication 2. <i>Journal of the National Cancer Institute</i> , 1978, 60, 1509-1513.	6.3	11
80	Some characteristics of natural cytostatic mouse splenocytes. <i>Journal of Immunological Methods</i> , 1981, 40, 193-208.	1.4	11
81	The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. <i>Immunology Letters</i> , 1988, 18, 181-189.	2.5	11
82	Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid Fc γ RII Expressing Tumor Cells. <i>Immunobiology</i> , 1992, 185, 415-425.	1.9	11
83	Inter-Tumor Heterogeneity – Melanomas Respond Differently to GM-CSF-Mediated Activation. <i>Cells</i> , 2020, 9, 1683.	4.1	11
84	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	3.3	11
85	The tumour microenvironment – Introduction. <i>Seminars in Cancer Biology</i> , 2002, 12, 87-88.	9.6	10
86	Presence and functions of immune components in the tumor microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2001, 495, 317-324.	1.6	10
87	Monoclonal antibodies from mice bearing polyoma virus-induced tumor. <i>Cancer Immunology, Immunotherapy</i> , 1982, 12, 217-224.	4.2	9
88	Do Naturally Occurring Antibodies Play a Role in the Progression and Proliferation of Tumor Cells?. <i>International Reviews of Immunology</i> , 1988, 3, 133-145.	3.3	9
89	The Metastatic Microenvironment. , 2013, , 15-38.		9
90	Antibody-dependent cell-mediated cytotoxic activity in syngeneic mouse ascites tumors. <i>International Journal of Cancer</i> , 1975, 16, 870-880.	5.1	8

#	ARTICLE	IF	CITATIONS
91	Autoantibody-Mediated Regulation of Tumor Growth. Annals of the New York Academy of Sciences, 1992, 651, 393-408.	3.8	8
92	TNF α and anti-Fas antibodies regulate Ly-6E.1 expression by tumor cells: A possible link between angiogenesis and Ly-6E.1. Immunology Letters, 1996, 54, 207-213.	2.5	8
93	The 5th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention Versailles, France, October 20 \AA 24, 2009. Cancer Microenvironment, 2010, 3, 1-5.	3.1	7
94	PHOX2B is a suppressor of neuroblastoma metastasis. Oncotarget, 2016, 7, 10627-10637.	1.8	7
95	<i>LY6S</i> , a New IFN-Inducible Human Member of the Ly6a Subfamily Expressed by Spleen Cells and Associated with Inflammation and Viral Resistance. ImmunoHorizons, 2022, 6, 253-272.	1.8	7
96	The immunosuppressive capacity of alloantisera in mice, including sera directed primarily against thymic antigens. Cellular Immunology, 1971, 2, 362-372.	3.0	6
97	Comparison of NK Activity in Mouse Spleen and Peripheral Blood Lymphocytes. Immunobiology, 1988, 177, 449-459.	1.9	6
98	IMMUNOSUPPRESSIVE ACTIVITY OF MOUSE ALLOANTIBODIES. Transplantation, 1969, 8, 516-519.	1.0	5
99	Separation of tumor-seeking small lymphocytes and tumor cells using percoll velocity gradients. Journal of Immunological Methods, 1981, 41, 43-56.	1.4	5
100	Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus. International Journal of Cancer, 2021, 148, 2321-2334.	5.1	5
101	Further studies on the determinant recognized by naturally-occurring murine autoantibodies reacting with bromelain-treated erythrocytes. Immunology Letters, 1988, 18, 191-200.	2.5	4
102	Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. Molecular Immunology, 1990, 27, 1219-1228.	2.2	4
103	Detection of immunoglobulin A anticardiolipin antibodies in cervical mucus from in vitro fertilization patients and fertile women. Fertility and Sterility, 1995, 64, 441-443.	1.0	4
104	Binding patterns of immunoglobulins from tumor-bearing mice to the corresponding tumor cells. Journal of Immunological Methods, 1978, 22, 37-49.	1.4	3
105	In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factor α mediated killing of c-Ha-ras-transformed cells. Cancer Immunology, Immunotherapy, 1992, 35, 388-394.	4.2	3
106	Myeloproliferation in long-term plasmacytoma-regressor mice. International Journal of Cancer, 1994, 56, 208-213.	5.1	3
107	Preleukemia in long-term plasmacytoma-regressor mice. , 1998, 76, 689-693.		3
108	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2

#	ARTICLE	IF	CITATIONS
109	Idiotypic-binding cells in plasmacytoma-bearing mice. <i>Cellular Immunology</i> , 1979, 44, 1-8.	3.0	1
110	The Pyst2-L phosphatase is involved in cell-crowding. <i>Immunology Letters</i> , 2006, 104, 138-145.	2.5	1
111	Effect in vivo of recombinant GM-CSF on neutropenia and survival in mice treated by high-dose melphalan. <i>European Journal of Haematology</i> , 1989, 43, 240-244.	2.2	1
112	Cellular selection and regulation in the immune response. <i>Journal of Immunological Methods</i> , 1975, 7, 145.	1.4	0
113	Immunological approaches to cancer therapeutics. <i>Journal of Immunological Methods</i> , 1983, 65, 274-275.	1.4	0
114	2-Deoxycoformycin and human hemopoietic cells in culture. <i>Developmental and Comparative Immunology</i> , 1984, 8, 931-937.	2.3	0
115	Does the dual-specificity MAPK phosphatase Pyst2-L lead a monogamous relationship with the Rek2 protein?. <i>Immunology Letters</i> , 2004, 92, 149-149.	2.5	0
116	Delivery of packaged mail in the tumor microenvironment. <i>Biochemical and Biophysical Research Communications</i> , 2019, 520, 705.	2.1	0
117	Tumor Microenvironment. , 2011, , 3797-3799.		0
118	Tumor Microenvironment. , 2017, , 4675-4679.		0